Brain Advance Access published online on April 8, 2003
Brain, doi:10.1093/brain/awg129
© 2003 by Guarantors of Brain
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
1 Rega Institute for Medical Research, Laboratories of Molecular Immunology and Immunobiology, University of Leuven, Leuven, Belgium
* Corresponding author. E-mail: ghislain.opdenakker{at}rega.kuleuven.ac.be.
Received 9 October 2002
; revised 16 January 2003
; accepted 16 January 2003
Parenteral administration of interferon (IFN)-
Keywords: gelatinase B; interferon; multiple sclerosis; inflammation; viral infection
Gelatinase B/matrix metalloproteinase-9 cleaves interferon-
and is a target for immunotherapy
is one of the currently approved therapies for multiple sclerosis. One characteristic of this disease is the increased production of gelatinase B, also called matrix metalloproteinase (MMP) 9. Gelatinase B is capable of destroying the blood-brain barrier, and of cleaving myelin basic protein into immunodominant and encephalitogenic fragments, thus playing a functional role and being a therapeutic target in multiple sclerosis. Here we demonstrate that gelatinase B proteolytically cleaves IFN-, kills its activity, and hence counteracts this cytokine as an antiviral and immunotherapeutic agent. This proteolysis is more pronounced with IFN--1b than with IFN--1a. Furthermore, the tetracycline minocycline, which has a known blocking effect in experimental autoimmune encephalomyelitis, an in vivo model of acute inflammation in multiple sclerosis, and other MMP inhibitors prevent the in vitro degradation of IFN- by gelatinase B. These data provide a novel mechanism and rationale for the inhibition of gelatinase B in diseases in which IFN- has a beneficial effect. The combination of gelatinase B inhibitors with better and lower pharmacological formulations of IFN- may reduce the side-effects of treatment with IFN-, and is therefore proposed for multiple sclerosis therapy and the immunotherapy of viral infections.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  N. Tamassia, V. Le Moigne, M. Rossato, M. Donini, S. McCartney, F. Calzetti, M. Colonna, F. Bazzoni, and M. A. Cassatella Activation of an Immunoregulatory and Antiviral Gene Expression Program in Poly(I:C)-Transfected Human Neutrophils J. Immunol., November 1, 2008; 181(9): 6563 - 6573. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Cheung, D. Marchant, E. K.-Y. Walker, Z. Luo, J. Zhang, B. Yanagawa, M. Rahmani, J. Cox, C. Overall, R. M. Senior, et al. Ablation of Matrix Metalloproteinase-9 Increases Severity of Viral Myocarditis in Mice Circulation, March 25, 2008; 117(12): 1574 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Minagar, J. S. Alexander, R. N. Schwendimann, R. E. Kelley, E. Gonzalez-Toledo, J. J. Jimenez, L. Mauro, W. Jy, and S. J. Smith Combination Therapy With Interferon Beta-1a and Doxycycline in Multiple Sclerosis: An Open-Label Trial Arch Neurol, February 1, 2008; 65(2): 199 - 204. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Van Lint and C. Libert Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation J. Leukoc. Biol., December 1, 2007; 82(6): 1375 - 1381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Bellehumeur, T. Collette, R. Maheux, J. Mailloux, M. Villeneuve, and A. Akoum Increased soluble interleukin-1 receptor type II proteolysis in the endometrium of women with endometriosis Hum. Reprod., May 1, 2005; 20(5): 1177 - 1184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Kieseier, J. J. Archelos, and H.-P. Hartung Different Effects of Simvastatin and Interferon Beta on the Proteolytic Activity of Matrix Metalloproteinases Arch Neurol, June 1, 2004; 61(6): 929 - 932. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Sotnikov, R. Hershkoviz, V. Grabovsky, N. Ilan, L. Cahalon, I. Vlodavsky, R. Alon, and O. Lider Enzymatically Quiescent Heparanase Augments T Cell Interactions with VCAM-1 and Extracellular Matrix Components under Versatile Dynamic Contexts J. Immunol., May 1, 2004; 172(9): 5185 - 5193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Gilli, A. Bertolotto, A. Sala, F. Hoffmann, M. Capobianco, S. Malucchi, T. Glass, L. Kappos, R. L.P. Lindberg, and D. Leppert Neutralizing antibodies against IFN-{beta} in multiple sclerosis: antagonization of IFN-{beta} mediated suppression of MMPs Brain, February 1, 2004; 127(2): 259 - 268. [Abstract] [Full Text] [PDF]
|
|